Actuate Therapeutics, Inc. (NASDAQ:ACTU) Short Interest Update

Actuate Therapeutics, Inc. (NASDAQ:ACTU) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 529,786 shares, a growth of 21.1% from the December 15th total of 437,439 shares. Based on an average daily trading volume, of 78,326 shares, the days-to-cover ratio is presently 6.8 days. Approximately 7.4% of the shares of the stock are short sold. Approximately 7.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 78,326 shares, the days-to-cover ratio is presently 6.8 days.

Actuate Therapeutics Stock Performance

Shares of ACTU stock opened at $5.56 on Wednesday. Actuate Therapeutics has a fifty-two week low of $5.08 and a fifty-two week high of $11.99. The company has a 50 day moving average price of $6.49 and a 200 day moving average price of $6.96. The stock has a market capitalization of $129.21 million, a P/E ratio of -6.39 and a beta of -0.15.

Actuate Therapeutics (NASDAQ:ACTU) last released its earnings results on Thursday, November 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02.

Insider Activity at Actuate Therapeutics

In other news, Director Todd S. Thomson sold 280,000 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $5.80, for a total value of $1,624,000.00. Following the transaction, the director directly owned 904,795 shares of the company’s stock, valued at approximately $5,247,811. This trade represents a 23.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 69.34% of the stock is owned by company insiders.

Hedge Funds Weigh In On Actuate Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ACTU. Sfmg LLC raised its holdings in Actuate Therapeutics by 32.3% in the second quarter. Sfmg LLC now owns 14,550 shares of the company’s stock valued at $89,000 after acquiring an additional 3,550 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Actuate Therapeutics by 98.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock valued at $151,000 after purchasing an additional 11,105 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Actuate Therapeutics by 61,068.0% in the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after purchasing an additional 15,267 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Actuate Therapeutics by 492.6% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock worth $113,000 after purchasing an additional 15,393 shares during the last quarter. Finally, New York State Common Retirement Fund purchased a new stake in shares of Actuate Therapeutics during the 2nd quarter worth $105,000.

Analyst Ratings Changes

A number of research firms have commented on ACTU. Weiss Ratings reiterated a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Monday, December 29th. Wall Street Zen cut Actuate Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Actuate Therapeutics in a research report on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Actuate Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $20.33.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.